AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted…